3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
2
Phase 1
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
2
Conditions
Breast Neoplasms
7
Brain Neoplasms
2
Stomach Neoplasms
1
Neoplasm Metastasis
1
HER2-positive Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Temozolomide
26
Bevacizumab
14
Radiosurgery
12
Radiotherapy
9
pembrolizumab
8
Carboplatin
8
Trastuzumab
6
temsirolimus
5
Sirolimus
5
Erlotinib Hydrochloride
5
abemaciclib
4
Paclitaxel
4
Irinotecan
4
Capecitabine
4
tipifarnib
3
Sorafenib
3
Radiation
3
Mental Status and Dementia Tests
3
Ipilimumab
3
Everolimus
3
Aminolevulinic Acid
3
130-nm albumin-bound paclitaxel
3
tucatinib
2
pertuzumab
2
fludarabine
2
durvalumab
2
alovudine
2
alectinib
2
Vorinostat
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Brain Neoplasms
×
tucatinib
×
Clear all
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled
NCT04512261
2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2
Withdrawn